Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 4INTERVENTIONAL

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Who May Be Eligible (Plain English)

Who May Qualify: \- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \< 10 mIU/ml) will be recruited. Who Should NOT Join This Trial: - Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine. - Those who had previous exposure to hepatitis B. - Post liver transplant patients. - Less than 18 years old. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: \- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer \< 10 mIU/ml) will be recruited. Exclusion Criteria: * Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine. * Those who had previous exposure to hepatitis B. * Post liver transplant patients. * Less than 18 years old.

Treatments Being Tested

BIOLOGICAL

Heplisav-B Injectable Product, 2-dose regimen

Investigators will randomly assign patients into a 2-dose regimen.

BIOLOGICAL

Heplisav-B Injectable Product, 3-dose regimen

Investigators will randomly assign patients into a 3-dose regimen.

Locations (1)

Mercy Medical Center
Baltimore, Maryland, United States